Literature DB >> 8238214

Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. The Silicone Study Group.

M S Blumenkranz1, S P Azen, T Aaberg, D C Boone, H Lewis, N Radtke, S J Ryan.   

Abstract

In the Silicone Study, 117 of 404 eyes (29%) with severe proliferative vitreoretinopathy (> or = C-3, full-thickness retinal folds in three or more quadrants) enrolled in the study were treated with vitrectomy, underwent a relaxing retinotomy, and were randomly assigned to treatment with long-acting gas or silicone oil. Forty-six eyes (20%) had undergone no previous vitrectomy (group 1); 71 eyes (42%) had undergone previous vitrectomy (group 2) with intraocular gas tamponade (P < .001). Group 1 eyes not undergoing retinotomy had better anatomic (six months) and visual (six and 24 months) outcomes and less hypotony (six months) than eyes that did regardless of tamponade (P < .05). For eyes undergoing retinotomy, silicone oil decreased the likelihood of hypotony (six months, P < .05). These differences were not found in group 2 eyes. We conclude that eyes undergoing a vitreous operation for the first time for the treatment of proliferative vitreoretinopathy can in most instances be successfully treated by conventional techniques without the need for relaxing retinotomy. Retinotomy may be required more often in patients undergoing repeat vitreous surgery for proliferative vitreoretinopathy, in which case both silicone oil and long-acting perflouropropane gas appear to be equally effective.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238214     DOI: 10.1016/s0002-9394(14)73196-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  27 in total

1.  Retinal redetachment after removal of intraocular silicone oil tamponade.

Authors:  J B Jonas; H L Knorr; R M Rank; W M Budde
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Is extreme surgery so extreme?

Authors:  D Wong
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

3.  Functional outcome and prognostic factors in 304 eyes managed by retinectomy.

Authors:  Vlassis G Grigoropoulos; Sarah Benson; Catey Bunce; David G Charteris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-22       Impact factor: 3.117

4.  Retrospective comparison of 25-gauge vitrectomy for repair of proliferative vitreoretinopathy with or without anterior proliferation.

Authors:  Tatsuhiko Sato; Kazuyuki Emi; Hajime Bando; Toshihide Ikeda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-07       Impact factor: 3.117

Review 5.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

6.  Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.

Authors:  Stephen G Schwartz; Harry W Flynn; Xue Wang; Ajay E Kuriyan; Samuel A Abariga; Wen-Hsiang Lee
Journal:  Cochrane Database Syst Rev       Date:  2020-05-13

Review 7.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

8.  Vitreoretinal endoscope for the assessment of the peripheral retina and the ciliary body after large retinectomies in severe anterior PVR.

Authors:  Frank Faude; Peter Wiedemann
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

9.  Relaxing retinotomies and retinectomies in the management of retinal detachment with severe proliferative vitreoretinopathy (PVR).

Authors:  Khaled Ag Shalaby
Journal:  Clin Ophthalmol       Date:  2010-10-05

Review 10.  Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.

Authors:  Stephen G Schwartz; Harry W Flynn; Wen-Hsiang Lee; Elizabeth Ssemanda; Ann-Margret Ervin
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.